Laboratory Corporation of America Holdings, also known as Labcorp, is a leading global life sciences company that is involved in deep scientific research and forward-thinking advancements in the medical field. The company is listed on the New York Stock Exchange under the ticker symbol 'LH'. Based in Burlington, North Carolina, Labcorp was established in 1978.
Labcorp’s mission is to improve health and improve lives. It caters to a range of clients – including physicians, hospitals, pharmaceutical and biotechnology companies, and patients directly. The company provides comprehensive clinical laboratory and end-to-end drug development services. Its areas of expertise are wide-ranging and include diagnostics, drug development, genomics, proteomics, and digital solutions.
Its diagnostics unit operates one of the largest clinical laboratory networks in the world, with more than 30 primary labs across the United States. It provides an array of routine and specialty testing services, such as allergy testing, genetic testing, oncology testing and more, allowing physicians to make informed and timely decisions.
Meanwhile, Labcorp's drug development unit, known as Covance, supports drug development and commercialization from preclinical to post-market. It offers solutions that generate higher quality and safer therapies to speed patient access to treatments.
Labcorp maintains a dedicated workforce of over 70,000 employees worldwide. The company’s achievements over the years have made a significant impact on the medical and scientific communities. Labcorp plays a pivotal role in advancing personalized medicine, transforming clinical trials, and improving patient care.
In 2020, Labcorp rose to the forefront of the global fight against the COVID-19 pandemic by providing COVID-19 testing solutions and playing a critical role in accelerating vaccine and treatment development. This further solidified the company's commitment to improving health and saving lives.
The Company maintains high ethical standards and is committed to doing business the right way by focusing on corporate responsibility. It aims to create a positive impact on society through environmental sustainability, community involvement, and responsible business practices.
In conclusion, Laboratory Corp of America Holdings is an indispensable part of the global health landscape. As they continue to innovate and support breakthroughs in the medical field, their work will remain essential in our collective effort to improve healthcare outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
HealthSource of Ohio has secured financing for a new $60 million medical facility in Batavia, Clermont County, with Fifth Third Bank providing the funding. The facility, which is a partnership between HealthSource of Ohio and UC Health, broke ground on October 20th. This development will expand medical services in the region.
Labcorp Director Richelle P. Parham sold 1,078 shares of Labcorp Holdings Inc. (NYSE: LH) common stock at $361.22 per share on October 30, 2026. This transaction was reported in a Form 4 filing with the SEC on November 3, 2026, leaving Parham with 2,288 shares directly owned. The sale was executed under transaction code "S."
Labcorp Director Richelle Parham sold 1,078 shares of the company's stock for approximately $389,395, reducing her direct holdings by 32.03%. The medical research company recently reported strong quarterly earnings, exceeding analyst estimates, and declared a quarterly dividend of $0.72 per share. Analysts generally maintain a "Moderate Buy" rating for Labcorp with an average price target of $365.67.
Waters Corporation reported robust Q3 2026 results with $1.767 billion in revenue, 9% organic growth, and 21% adjusted EPS growth, driven by strong performance in Analytical Sciences and a significant rebound in Biosciences China. The company raised its full-year 2026 revenue guidance by $43 million and provided an optimistic 2027 outlook, emphasizing strategic initiatives like AI integration, new product launches, and the MOBILion Systems acquisition to achieve high single-digit growth potential. Waters also highlighted its unique position in pharma QC with AI-powered Empower features and growing demand from AI-native biotech companies.
Revvity reported strong Q3 2026 financial results with 7% pro forma organic growth, driven by a 9% increase in the life sciences segment and solid performance in diagnostics. The company exceeded adjusted EPS expectations and raised its full-year organic growth and EPS guidance, attributing success to improving market demand, expanding AI-related opportunities across its portfolio, and operational efficiencies. New product launches in software and diagnostics also contributed to the positive outlook.
Shares of Natera (NTRA) fell 8.5% on Monday, November 2, 2026, despite no company-specific news, as the broader market also experienced a soft day, particularly impacting fast-growing, unprofitable companies. Natera's peers in the healthcare sector also saw declines, with Natera experiencing the largest drop among them. Despite this recent dip, Natera's stock has shown significant long-term growth, outperforming the S&P 500 over the past year.
Shares of Labcorp Holdings Inc. (LH) fell 1.60% to $355.59 on Monday, experiencing its second consecutive day of losses. This occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. Despite the daily loss, the article headline suggests Labcorp outperformed its competitors.
Charles River Laboratories International is leveraging AI through partnerships, including one with Ipsen for its Virtual Control Group database in toxicology and another with Labcorp and the FDA to assess medicine abuse potential. These initiatives aim to shift the company's focus towards higher-value preclinical services and improve drug candidate progression efficiency, which could positively impact its financial narrative by moving towards profitability despite existing challenges like high debt and potential shifts to non-animal testing. The financial impact, however, hinges on broader adoption and regulatory acceptance of these new methodologies.